Answers are grounded in this paper and cite their sources.
Despite their name, borderline rpoB mutations are correlated with unfavourable outcomes when rifampicin-throughout treatment is used. They may become the drivers of rifampicin-resistant tuberculosis. Second-line treatment is recommended. https://bit.ly/3nbkZjt
No takes yet. Share an insight, caveat, or question.
Deun et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: